Your Early Detection and Diagnosis newsletter ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏
| | | | In this edition of the Early Detection and Diagnosis newsletter, we have exciting results from two #CRUKFunded studies, opportunities to join our critical peer review panels, plus advice on using AI in your research, cross-discipline events and more.
But first, I’m excited to announce Peter Kuhn, Serena Nik-Zainal and Suzette Delaloge as our keynote speakers at the Early Detection of Cancer Conference 2025. |
|
|
|
|
|
|
The conference, in its 10th year, continues to be a fantastic opportunity to mingle with experts in early detection from around the world, to take in new research and make the critical connections that will drive progress in early detection for patients everywhere.
Join us from 21-23 October in Portland, US, for inspiring insights from Peter, Serena and Suzette as well as our soon-to-be-announced speaker line-up of leaders in early detection research. |
| | |
|
|
|
|
|
Kind regards,
David Crosby
Head of Prevention and Early Detection Research
Cancer Research UK |
|
| | |
|
|
|
|
Upcoming funding deadlines |
|
| | |
|
|
CRUK-Funded: interim results from the BRAID trial |
| A large-scale trial has indicated that extra scans used in breast cancer screening could treble cancer detection for a subset of women with very dense breasts, potentially saving up to 700 lives a year in the UK.
BRAID is the first trial to directly compare supplemental imaging methods and demonstrate their value for early cancer detection as part of widespread screening.
The team, led by Fiona Gilbert at the University of Cambridge, hope their results will be used to enhance screening programmes in the UK and globally to diagnose more cancers early. |
| | |
|
|
|
 | | | | We are offering more opportunities than ever before to showcase your work at the Early Detection of Cancer Conference 2025, with posters, lightning talks and the all-new poster pitches.
What is a poster pitch?
A poster pitch is a great opportunity to encourage attendees to visit your poster.
Fun and fast-paced, you will take to the stage with 60 seconds and one slide to make your work stand out from the crowd.
Submit your abstracts for any of these opportunities today for the chance to present your early detection work to the international research community in October.
Abstracts submissions close on 20 June. | | |
| |  | | | | The Early Detection of Cancer Conference is a part of a long-term commitment by Canary Center at Stanford, OHSU Knight Cancer Institute and Cancer Research UK to drive groundbreaking research in the early detection and diagnosis of cancer.
As an #EDxConf25 sponsor, you will be at the heart of this critical work.
Join experts from across the research continuum for three days of networking and knowledge-sharing to spark innovative ideas and new collaborations.
Make sure you and your brand are part of the action this year; get in touch to discuss sponsorship options today. | | |
|
|---|
|
|
|
|
CRUK-Funded: study identifies “cell of origin” in LUSC |
| A team from University College London (UCL), the Wellcome Sanger Institute and the University of Cambridge have identified the “cell of origin” in lung squamous cell carcinoma (LUSC) and how it becomes dominant in the lung.
Observing how a population of basal cells in the trachea outcompeted other cell types, invading and occupying large areas of the lung, the team identified these cells, which express the Krt5 gene that helps build cell structure, as the origin point for LUSC to develop.
Sam Janes, a senior author of the study, said in UCL’s report, “By understanding the ‘cell of origin’ where these changes begin and how they develop, the ambition is that we will be able to design strategies to prevent lung cancer occurring in the first place or at least detect it much earlier.” |
| | |
|
|
|
Deadline approaching: apply to join our College of Expert Peer Reviewers |
| The deadline for applications to join our College of Expert Peer Reviewers is fast approaching.
We’re growing our diverse, multi-disciplinary community of peer reviewers and are seeking applications to join our critical peer review panels, including:
• Early detection and diagnosis biology, markers, technology and data research
• Early detection and diagnosis trials, behavioural, health systems and health economics research
If you want to help shape decisions on research funding that will impact the future of early detection, submit your application by 6 June.
Head to our website to find out more about the roles, eligibility criteria and how to apply. |
| | |
|
|
|
Do you have questions about applying your early detection research to cancer prevention? |
| Join our City of London Centre for a one-day, in-person “Primer on Cancer Prevention” to learn the fundamentals of cancer prevention from experts in the field.
Peter Sasieni, of the Wolfson Institute of Population Health, is one of the event co-hosts, and gave us an insight into what attendees can expect:
“We’ll give a taster of four perspectives – the lab, the clinic, epidemiology and behavioural science. This will allow us to bring together what we understand about cancer prevention at the molecular level with societal questions about how to change behaviours.”
So, if you have questions about how your early detection research could be applied in the context of cancer prevention, this is the event for you.
Register today to join Peter Sasieni and co-hosts at the Primer in London on 24 June.
Please note that registration for the Primer event does not include attendance to the Cancer Prevention Research Conference 2025. |
| | |
|
|
|
The pitfalls and potential of generative AI |
| As universities wrestle with how to address the impact of generative AI on many levels, what does it mean on an individual level for a postdoc or PhD student in a lab interested in using generative AI to support their work?
A few years on in the generative AI revolution, Cancer Research UK Manchester Institute’s Andrew Porter looks at where we are now with AI tools and what researchers need to think about before diving in.
Read Andrew’s latest column in our “Research with Integrity” column on Cancer News for a balanced take on the opportunities, risks and considerations of using generative AI in your research. |
| | |
|
|
|
The Pre-Cancer State and interception opportunities at #PrevConf25 |
| Are you interested in hearing what’s new in pre-cancer biology? Join us for a series of engaging scientific sessions at the Cancer Prevention Research Conference 2025!
On Day 1, Simon Leedham (University of Oxford) and Irene Ghobrial (Havard Medical School) will co-chair a session on “Pre-cancer biology and interception opportunities,” joined by Margaret Fabre (AstraZeneca), Jen Morton (Cancer Research UK Scotland Institute) and Doug Winton (Cambridge Stem Cell Institute).
This is followed on Day 2 by a panel discussion on “Defining the Pre-Cancer State to enable innovations in preventive intervention.” The session will be chaired by Laura Wood (John Hopkins University School of Medicine), with speakers Sam Janes (UCL), Marnix Jansen (UCL Cancer Institute) and Phil Jones (University of Cambridge).
Join us to discuss the latest studies and thinking in pre-cancer biology research with experts in the field at #PrevConf25 from 25-27 June in London, UK. |
| | |
|
|
|
New funding for UK-US teams |
| We are now jointly considering applications to our Biology to Prevention Award with the American Cancer Society. Up to the equivalent of £1.2m is on offer to collaborative UK-US research teams for primary prevention research. |
|
| | | | Do you know someone who could benefit from this new co-funding?
Forward this email to your team or share the news with your network:
| Share on: | | |
|
|---|
|
|
|
Been forwarded this email? Subscribe to our newsletter to receive bimonthly early detection and diagnosis research updates. |
| | |
|
|
|
| | Together we are
beating cancer |
| | |
|---|
|
|
|
| | | You are playing a crucial role in helping us beat cancer, so we'd like to continue to keep you updated on what we're up to. You can manage your preferences and unsubscribe here.
Your details are safe with us. Check out our Privacy Policy.
Our supporters are at the heart of everything we achieve at Cancer Research UK. Read our Fundraising Promise.
This email is from Cancer Research UK. Cancer Research UK is a registered charity in England and Wales (1089464), Scotland (SC041666), the Isle of Man (1103) and Jersey (247). A company limited by guarantee. Registered company in England and Wales (4325234) and the Isle of Man (5713F). Registered address: 2 Redman Place, London, E20 1JQ. |
|
|
|
